Background-Vascular Ehlers-Danlos syndrome (VEDS) causes reduced life expectancy because of arterial dissections/ rupture and hollow organ rupture. Although the causative gene, COL3A1, was identified >20 years ago, there has been limited progress in understanding the disease mechanisms or identifying treatments. Methods and Results-We studied inflammatory and transforming growth factor-β (TGF-β) signaling biomarkers in plasma and from dermal fibroblasts from patients with VEDS. Analyses were done in terms of clinical disease severity, genotype-phenotype correlations, and body composition and fat deposition alterations. VEDS subjects had increased circulating TGF-β1, TGF-β2, monocyte chemotactic protein-1, C-reactive protein, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and leptin and decreased interleukin-8 versus controls. VEDS dermal fibroblasts secreted more TGF-β2, whereas downstream canonical/noncanonical TGF-β signaling was not different. Patients with COL3A1 exon skipping mutations had higher plasma intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, and VEDS probands had abnormally high plasma C-reactive protein versus affected patients identified through family members before any disease manifestations. Patients with VEDS had higher mean platelet volumes, suggesting increased platelet turnover because of ongoing vascular damage, as well as increased regional truncal adiposity. Conclusions-These findings suggest that VEDS is a systemic disease with a major inflammatory component. C-reactive protein is linked to disease state and may be a disease activity marker. No changes in downstream TGF-β signaling and increased platelet turnover suggest that chronic vascular damage may partially explain increased plasma TGF-β1. Finally, we found a novel role for dysregulated TGF-β2, as well as adipocyte dysfunction, as demonstrated through reduced interleukin-8 and elevated leptin in VEDS. (Circ Cardiovasc Genet. 2014;7:80-88.)
V ascular Ehlers-Danlos syndrome (VEDS), formerly known as type IV EDS, leads to reduced life expectancy because of arterial dissections and rupture, as well as hollow organ rupture, with life-threatening complications occurring as early as the second decade of life. 1 Despite the identification of the causative gene, COL3A1, >2 decades ago, [2] [3] [4] there has been limited progress on understanding the disease mechanism beyond that of connective tissue weakness because of structural defects or reduced amounts of type III procollagen. The only human treatment intervention trial to date was modestly beneficial to arterial complications using celiprolol, a mixed β(1)-adrenoceptor antagonist and β(2)-adrenoceptor agonist that is not available in the United States. 5 Although the drug mechanism remains unclear, a protective role for transforming growth factor-β (TGF-β) has been suggested. 5 In a COL3A1 haploinsufficiency mouse model study, doxycycline, a matrix metalloproteinase inhibitor, reduced arterial lesions. 6 Whether this will be applicable to other mutations that disrupt the collagen triple helix is not known nor have the results been validated in humans.
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The COL3A1 gene product, procollagen III, is processed to form the mature collagen III homotrimer. The most common COL3A1 mutations in VEDS are missense resulting in the substitution of other amino acids for glycine located throughout the triple-helical domain, with the next most common being splice site mutations that lead to single exon skipping (ES). 1, 7 These mutation classes result in a dilated endoplasmic reticulum in skin fibroblasts, reduced type III procollagen secretion, elastic fiber abnormalities, and alterations in the size and distribution of the major collagen fibrils through a dominant negative mechanism. 8 By contrast, haploinsufficiency null mutations that act via a protein deficiency mechanism result in a milder clinical phenotype with delayed vascular complication onset and absence of hollow organ rupture. 9, 10 Comparing these patient groups based on mutation type and disease severity by disease-related biomarkers can help to delineate the disease process resulting from abnormally structured type III collagen.
With the emerging role of the TGF-β pathway in genetically mediated aneurysm syndromes such as Marfan syndrome (MFS) [11] [12] [13] and the identification of multiple TGF-β-related genes that cause syndromes phenotypically overlapping with VEDS, [14] [15] [16] we sought to study the role of this pathway in VEDS pathogenesis using patient-derived fibroblast cell lines and plasma. The 3 mammalian TGF-β isoforms, TGF-β1, TGF-β2, and TGF-β3, are known to regulate diverse biological processes and maintain tissue homeostasis; their functions are dependent on the relative expression of the isoforms in vivo. 17 In light of the catastrophic disease progression seen in some patients, 18 we quantified circulating biomarkers involved in vascular inflammation (TGF-β1, TGF-β2, monocyte chemo-
and their role in the natural history of VEDS. Because access to vascular tissue through clinical care is limited, dermal fibroblasts have been used to study features of genetic disorders, [19] [20] [21] which we used to study TGF-β biomarkers. The pleiotropic phenotypes seen in the VEDS setting, such as alterations in body composition and fat deposition and related biomarker expression (interleukin-8 [IL-8], leptin, adiponectin), clinical disease severity, and genotype-phenotype analyses, were correlated to biomarker concentrations to identify disease markers and treatment targets. In addition to evidence of systemic inflammation, we found a novel role for dysregulated TGF-β2 and adipocyte dysfunction as demonstrated through reduced IL-8 and elevated leptin in VEDS.
Methods

Study Subjects
All study patients were enrolled in protocol no. 2003-086, approved by the MedStar Health and the National Institute on Aging Institutional Review Board, and provided informed consent. Age-and sex-matched healthy controls were obtained from the Baltimore Longitudinal Study of Aging. Dual-energy x-ray absorptiometry studies on patients and Baltimore Longitudinal Study of Aging controls were performed on a GE Lunar Prodigy Advance scanner. Control plasma and skin biopsy samples were obtained with informed consent at the National Institute on Aging (no. 2003-086 and 2003-071). Additional deidentified human dermal fibroblasts from apparently healthy subjects with normal chromosomes and low passage were obtained from the Coriell repository (http://ccr.coriell.org). All disease complications occurred at least a year before sample collection, and patients were not acutely ill.
Genetic Mutation Analysis
All VEDS subjects included in this study have a pathogenic mutation confirmed in COL3A1. Details are available in the Data Supplement.
Fibroblast Cell Culture and ELISA Assays
Dermal fibroblasts were cultured from a 4-mm punch skin biopsy. Culture conditions, immunoblot methods, and biomarker ELISA methods are available in the Data Supplement.
COL3A1 Gene Silencing by Allele-Specific Small
Interfering RNA (siRNA) COL3A1 allele-specific gene silencing and protein knockdown in a VEDS patient fibroblast cell line with a glycine mutation [c.755G>T (G252V)] was performed as previously described. 22 Details are available in the Data Supplement. Experiments were done in triplicate.
Mean Platelet Volume and Clinical CRP Measurements
Clinical testing for mean platelet volume (MPV) and platelets (n=35 VEDS, 74 controls) was done using a Clinical Laboratory Improvement Amendments-certified, automatic blood counter (Sysmex XE-5000 Analyzer, Sysmex America, Inc, Lincolnshire, IL), and clinical CRP was measured from serum separator tubes using a Dimension Vista 3000T analyzer (Siemens, Erlangen, Germany) in the Harbor Hospital Clinical Laboratory, Baltimore, MD.
Statistical Analysis
Comparisons were made with the unpaired Student t test to assess mean differences. All P values are 2-tailed and considered significant when ≤0.05. Data are represented as mean±SEM. Because of the potential for correlations induced by related subjects, we also considered generalized estimating equations with an exchangeable correlation structure as an alternative method of comparison in assays that used related subjects. The normality of the data was checked by constructing quantile-quantile plots of each sample and biomarker. All statistical analyses were done using Microsoft Excel 2010 and R 2.10.1.
Results
VEDS Clinical Features
In our clinical cohort of 41 VEDS subjects, 30 were women (73.2%) and 11 were men (26.8%). Cardiovascular medications taken at the time of biological sample collection are listed in the Table. All patients were normotensive at the time of sample collection. Institutional review board approval did not allow for cardiovascular medication removal before the study visit.
Patients who have an arterial or a bowel event leading to a VEDS diagnosis are indicated in the Table. Two patients (patients 8 and 34) with ES mutations were identified as VEDS through severe bruising before experiencing an arterial or a bowel rupture. Thirteen patients were identified as VEDS through family members before any manifestations themselves, which we termed Identified Through Family History (ITFH); familial relationships in the cohort are indicated (Table) .
Genetic Analysis
Pathogenic mutations in COL3A1 included 19 patients with a glycine substitution in the collagen triple helix (gly), 26 10 patients with a splice site mutation resulting in ES, 27 8 patients with a null mutation resulting in haploinsufficiency (null), 10 2 patients with a small insertion/deletion (indel), 1 patient with a large deletion (del), and 1 patient with a missense mutation resulting in a Pro-Ser change (Table) . Mutations were submitted to the EhlersDanlos Syndrome Variant Database (http://eds.gene.le.ac.uk).
The missense mutation resulting in a proline to serine substitution in COL3A1 was not reported as a single-nucleotide polymorphism in the 1000 genomes (http://www.1000genomes. org) or in >6500 exomes on the Exome Variant Server (http:// evs.gs.washington.edu/EVS). In silico analysis (PROVEAN, http://provean.jcvi.org; SIFT, http://sift.jcvi.org; PolyPhen-2, http://genetics.bwh.harvard.edu/pph2) identified this mutation February 2014 ACE1 indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, aspirin; BB, β-blocker; CCB, calcium channel blocker; del, deletion; ES, splice site mutation resulting in skipping of the exon; F, female; Gly, glycine substitution in the collagen triple helix; indel, insertion/deletion; ITFH, identified through family history; M, male; null, null mutation resulting in haploinsufficiency; and ST, statin.
*Nomenclature is based on the coding sequence of the COL3A1 gene (ENSG00000168542) with the adenosine of the annotated translation start codon defined as nucleotide position +1.
†Proband not part of the study.
as pathogenic. Several of these mutations have been previously identified in other studies as indicated in the Table.
Circulating TGF-β Cytokines and Secretion From Dermal Fibroblasts
We analyzed plasma samples from 35 VEDS subjects and 74 age-, sex-, and body mass index-matched controls matching ≥1:2. Circulating TGF-β1 was significantly higher in VEDS subjects versus controls (8.3±1.1 versus 2.5±0.4 ng/ mL; P<0.0001). Similarly, VEDS subjects had significantly increased circulating total TGF-β2 in plasma (152.2±6.3 versus 101.3±2.0 pg/mL; P<0.0001; Figure 1A ). TGF-β3 was measured, but all samples were below the lower detection limit. Total TGF-β1 and TGF-β2 secretion from isolated human skin fibroblasts was measured in a subset of 33 subjects who provided biopsy samples and whose cell lines provided adequate in vitro cell growth, including 17 VEDS subjects (12 F/5 M, representing 7 gly, 3 ES, 3 null, and 4 other mutations) and 17 controls, who were chosen at random from the initial 74 by a blinded technician. TGF-β1 and -β3 secretion was not significantly different between groups (data not shown). However, secreted TGF-β2 was significantly elevated (47.9±0.7 versus 42.9±0.8 pg/mL per milligram protein; P<0.0001) in VEDS subjects versus controls ( Figure 1B ). Although the secretion difference was only ≈15%, the results were highly significant and recapitulated those from plasma. Plasma and in vitro secreted TGF-β2 levels were positively correlated (r=0.53).
Downstream TGF-β Biomarkers in Dermal Fibroblasts
Downstream canonical TGF-β biomarkers treated with TGF-β1 (pSmad2, pSmad1/5/8) and untreated noncanonical (extracellular signal-regulated kinase1/2, p-p38 mitogenactivated protein kinase) markers were analyzed by Western blot in the same subset of dermal fibroblasts as above (n=17 VEDS, 17 controls). No significant differences (P>0.05) were found in these proteins between patients with VEDS and controls (Figure 2A and 2B) when normalized to either loading controls or total protein for phosphorylated markers. In addition, there were no quantitative differences between the TGF-β receptor I and II in untreated VEDS and control fibroblasts (data not shown). The same results seen with TGF-β1 stimulation were found with TGF-β2 stimulation (data not shown). To investigate possible biomarkers further, a human TGF-β/bone morphogenetic protein signaling pathway mRNA array was used to screen genes of interest; quantitative polymerase chain reaction was used to validate any potential gene hits. On validation, no pathway genes were found to differ between patients with VEDS and healthy controls (see Data Supplement).
COL3A1 Allele-Specific siRNA Treatment
To further confirm that a dominant negative COL3A1 mutation in VEDS was not affecting downstream TGF-β signaling, we used allele-specific siRNA knockdown in fibroblasts from a VEDs patient with a c.755G>T (G252V) mutation in COL3A1 as previously described. 22 This knockdown essentially converted a Gly-type COL3A1 mutation to a haploinsufficient mutation, allowing us to study the presence of abnormally structured collagen fibrils versus qualitative deficiency of type III collagen influence on TGF-β downstream signaling. Figure 3A shows that COL3A1 mRNA and protein were knocked down compared with randomized siRNA. The TGF-β biomarkers were again tested by Western blot and showed no differences between the VEDS sample with the mutant allele knocked down and the same sample with the Gly mutation intact ( Figure 3B ).
Inflammatory Biomarkers and Adipokines in EDTA Plasma
VEDS plasma concentrations of MCP-1, CRP, ICAM-1, and VCAM-1 as well as leptin were all significantly elevated, whereas IL-8 was significantly decreased versus age-and sexmatched controls (P=0.001, P=0.046, P=0.0004, P=0.0006, P=0.006, P<0.0001, respectively; Figure 4A -4F). Plasma CRP concentrations were confirmed using a clinical immunoassay, and they were highly and positively correlated with the multiplex CRP assay (r=0.93). TNF-α, serum amyloid A, and adiponectin were not significantly different between groups according to a Meso Scale Discovery multiplex assay (data not shown). IL-8 secretion by ELISA was not significantly different, and IL-8 receptor I (C-X-C chemokine receptor type 1) was not detectible in fibroblasts by Western blot or quantitative polymerase chain reaction. IL-2, IL-6, granulocyte-macrophage colony-stimulating factor, interferon-γ, IL-10, IL-12, and IL-1β were assayed in VEDS and control samples but were below the standard curve limits according to an MSD multiplex assay (data not shown). Circulating biomarkers in VEDS were compared with a cohort of MFS patients (n=20). CRP and SAA were different between groups, with CRP significantly elevated (P=0.046) in VEDS but not MFS (P=0.075) and SAA significantly elevated in MFS (P=0.037) but not in VEDS (P=0.074; see Data Supplement Table I ).
Because haploinsufficient patients with VEDS reportedly have a milder phenotype and later onset of complications, 9, 10 all biomarkers (TGF-β1, TGF-β2, MCP-1, CRP, ICAM-1, A, Box-and-whisker plots reveal elevated total TGF-β1 and -β2 in platelet-poor EDTA-plasma from VEDS subjects (n=35) vs healthy controls (n=74). B, Box-andwhisker plots reveal secreted total TGF-β2, but not TGF-β1 or -β3, from VEDS subject fibroblasts (n=17) is elevated vs healthy controls (n=17) ex vivo. Secretion data are normalized to protein concentration. February 2014 VCAM-1, IL-8, and leptin) were correlated to the individual mutation type and patient clinical history (ie, probands versus ITFH). ICAM-1 and VCAM-1 were significantly higher in the ES group versus the gly group (P=0.05 and P=0.006, respectively) and the null group (P=0.02 and P=0.01, respectively; Figure 5A ). CRP was significantly higher in patients identified as probands versus ITFH (P=0.01; Figure 5B ). ICAM-1 and VCAM-1 also showed a similar trend to CRP with increases in the probands versus the ITFH group, but results were not statistically significant (P>0.05). None of the other biomarkers studied showed a significant difference between groups, indicating that, with the exception of CRP, disease severity or complications were not factors.
To determine whether medications taken by the patients with VEDS at the time of sample collection affected the circulating and secreted biomarkers, their concentrations were analyzed as above. Specifically, only medications with known cardiovascular effects were considered, including β-blockers (n=16), statins (n=7), and aspirin (n=6), whereas angiotensin receptor blockers (n=4), angiotensin-converting enzyme inhibitors (n=3), and calcium channel blockers (n=3) were not included because of insufficient sample size. Eighteen patients were on none of these medications. For the remaining individual groups, the levels of TGF-β1, TGF-β2, MCP-1, CRP, ICAM-1, VCAM-1, IL-8, and leptin remained significantly higher (or lower for IL-8) in the VEDS/β-blocker group versus controls (P≤0.05, same trend as entire VEDS cohort regardless of drug intervention, in Figures  1 and 4 ). For patients with VEDS on statins, only plasma TGF-β2 and IL-8 remained significantly higher and lower, respectively, than controls (P≤0.05). For patients with VEDS using aspirin, plasma TGF-β2, MCP-1, and IL-8 remained significantly higher and lower (IL-8), respectively, than controls (P≤0.05). Patients who had a previous event taking the above medications had significantly elevated IL-8 in circulation (P=0.007) versus patients without a previous event taking the above medications.
VEDS Body Composition Analysis
Dual-energy x-ray absorptiometry scans that include body composition data 28 were available in a subset of patients with VEDS (n=20; 13 of 20 probands; 7 of 20 ITFH; 9 gly; 4 ES; 4 null; 3 other mutation) who were found to have an altered body fat distribution versus age-, sex-, and body mass indexmatched controls (n=17; nominal values in Data Supplement Table II ). The body mass index and total body fat mass were not significantly different (P>0.05); however, truncal fat was significantly increased in VEDS versus controls (P<0.001). The leg fat/total fat ratio was significantly decreased in VEDS (P<0.001), whereas the trunk fat/total fat ratio was significantly increased in VEDS (P<0.001) versus controls ( Figure 6 ). We found a weak, positive correlation between TGF-β1 and trunk fat (r=0.16) in patients who had an event and a weak, negative correlation between TGF-β1 and trunk fat (r=-0.22) in patients who did not suffer an event.
Mean Platelet Volume
The MPV, a platelet turnover indicator, was significantly elevated in VEDS versus healthy controls (P=0.0007), although there were no significant differences in the absolute platelet counts (P>0.05; Figure 7 ). MPV remained significantly ICAM-1) , and vascular cell adhesion molecule-1 (VCAM-1) in platelet-poor EDTA-plasma from VEDS subjects (n=35) vs healthy controls (n=74). Samples were assayed using an immuno-multiplex system. E, Reduced interleukin-8 (IL-8) is seen in platelet-poor EDTA-plasma from VEDS subjects vs healthy controls. F, Significantly increased leptin in platelet-poor EDTA-plasma by ELISA from VEDS subjects vs healthy controls is seen. elevated in the proband (P=0.02) and ITFH (P=0.01) subgroups versus controls.
Discussion
TGF-β signaling pathway abnormalities have been implicated in several connective tissue dysplasias with some overlapping but distinct phenotypes. In VEDS, the aneurysms and dissections usually occur in the medium-sized arteries rather than the aortic root, 1 and there is no evidence of long-bone overgrowth seen in MFS, where mutations in FBN1 lead to increased circulating TGF-β1 29 and intracellular TGF-β1 signaling.
12,13
In Loeys-Dietz syndrome, mutations in TGFBR1, TGFBR2, TGFB2, and SMAD3 may result in vascular, obstetric, and skin abnormalities similar to VEDS. [14] [15] [16] 30, 31 However, features such as bifid uvula, hypertelorism, and craniosynostosis are not found in VEDS. TGF-β2 deficiency is known to cause developmental defects involving the heart, lung, limb, spinal column, and craniofacial systems in animal models and inactivating mutations in TGFB2 lead to familial thoracic aortic aneurysm with paradoxically elevated TGF-β2 in tissue. 15, 32, 33 We found that proinflammatory markers TGF-β1, TGF-β2, MCP-1, CRP, ICAM-1, and VCAM-1 were elevated, and IL-8 was decreased in circulation in VEDS subjects versus controls. No differences were found between probands and patients with VEDS who were identified through relatives and who had no complications themselves, indicating that elevated TGF-β1 and -β2 may correlate to having the disease but not necessarily to disease severity or activity. MPV, a platelet turnover indicator, was significantly increased in VEDS. TGF-β1 is known to be abundant in platelets, 34 which was the rationale for performing measurements in platelet-free plasma. Ongoing microvascular damage, even in younger patients without complications, may lead to increased platelet turnover, degranulation, and subsequent TGF-β1 release into circulation as recently described in a mouse model of cardiac pressure overload. 35 Interestingly, we found that CRP was not significantly elevated in MFS, suggesting a different biomarker profile from VEDS.
Cardiovascular medication use in patients with VEDS modulated TGF-β1, MCP-1, CRP, ICAM-1, VCAM-1, and leptin levels. ICAM-1 and VCAM-1 correlated with VEDS severity. Although the exact role of these proteins is unclear, both markers are increased in atherosclerotic lesions in human coronary arteries, 36 indicating a role in injury response. MCP-1 mediates vascular inflammatory cell adhesion and contributes to neointimal hyperplasia in arterial injury. 37 Elevated CRP is seen in acquired autoimmune disorders and concentrations correlate with inflammation extent and severity. 38 Increased CRP has been found in patients with osteoarthritis and progressive joint damage, 39 as well as coronary disease. 40 We postulate that there is underlying chronic vascular damage in VEDS that alters the vascular environment and may lead to a state of systemic inflammation (MCP-1 and CRP elevation), which may contribute to adverse clinical outcomes. Although CRP levels did not correlate with mutation type, the significant increase in probands versus patients with ITFH suggests that CRP may be a disease activity indicator; therefore, monitoring CRP levels in patients with VEDS should be considered. If elevated, we would recommend shorter arterial surveillance intervals and a low threshold for working up new symptoms/signs with imaging studies. We would also recommend aggressively addressing all cardiovascular risk factors that increase aneurismal event risk (eg, elevated blood pressure, abnormal lipids, smoking) to improve outcomes.
Secreted TGF-β2, but not TGF-β1, from VEDS fibroblasts was elevated versus controls. TGF-β2 is much less abundant than TGF-β1 in circulation and in tissues, 34 and the finding of excess circulating levels and increased secretion ex vivo in extracellular matrix-producing cells allows the possibility for a role of TGF-β2 in VEDS pathogenesis, different from that of TGF-β1. Interestingly, Western blot analysis of downstream TGF-β biomarkers and mRNA analysis of TGF-β pathway genes in fibroblasts did not reveal any differences between VEDS subjects and controls. Furthermore, treating fibroblasts of a patient with VEDS with allele-specific siRNA, which converted the gly-type mutation to a null-type, showed that suppressing the structurally abnormal type III collagen did not alter TGF-β signaling downstream of the receptors. Dermal fibroblasts historically have been used to study VEDS because the disease has a strong skin phenotype, mimicking the fragility found in vascular tissues. Therefore, we found it noteworthy that the underlying genetic defect did not impair intracellular TGF-β signaling in this setting when the expectation would be that it should. Although intracellular changes were not found in fibroblasts, it is possible that studying other cell types (eg, vascular smooth muscle) may demonstrate an effect. The lack of available direct tissue for study precluded the investigation of TGF-β1 and TGF-β2 or downstream targets in VEDS arteries. However, this could be undertaken in the future, especially through development of an animal model recapitulating the vascular complications of VEDS, specifically, medium-sized artery aneurysms and dissections. An appropriate animal model does not currently exist.
Interestingly, TGF-β2 and IL-8 were the only analytes in plasma unaffected by the drug treatments. IL-8 was decreased in VEDS versus controls. IL-8 plays an important role in angiogenesis, 41, 42 and TGF-β1 inhibits IL-8 secretion during active inflammation in the vascular endothelium, consistent with our findings. 43 A potential role for reduced IL-8 in VEDS and related aneurismal disorders is intriguing and warrants further study. Although the absence of modulation by cardiovascular medications suggests that TGF-β2 and IL-8 may have intrinsic correlations to the disease, caution needs to be exercised in interpreting these data because the study design does not allow for a rigorous analysis of drug effects. Leptin levels were significantly increased (but adiponectin unchanged) in VEDS plasma. Body composition analysis showed that patients with VEDS have increased truncal fat mass versus controls. Excess TGF-β1 release by human adipose tissue in obesity has been described but not TGF-β2 44 ; however, our study subjects are not obese. In a recent study of an Italian VEDS cohort, a similar truncal fat distribution was seen versus controls, suggesting that this is not a diet-dependent effect. 45 In the general population, regional adiposity is known to be associated with arterial stiffness through the influence of leptin. 46 Abdominal adiposity markers have a graded and significant association with risk of stroke/transient ischemic attack. 47 In VEDS, the vascular condition is inborn and predates the fat deposition pattern. Although the sample size was small, we found a weak correlation between TGF-β1 and trunk fat in patients who had an event. Therefore, it is possible that vascular inflammation is leading to the abnormal truncal fat accumulation rather than the reverse. However, a prospective study would be needed to confirm this hypothesis.
There are several limitations to this study. We used available dermal fibroblasts because an appropriate mouse model and arterial tissues were not available. Although we expect to see a phenotype in VEDS dermal fibroblasts, we acknowledge that other types of extracellular matrix-producing cells, such as vascular smooth muscle, may yield different results. A VEDS mouse model would permit a more thorough TGF-β pathway examination at the tissue level, which again was not feasible with the study's limited human samples. Samples sizes were relatively limited in this study; therefore, analyses in a larger cohort are warranted to confirm the results. We were unable to perform uniform and exhaustive vascular imaging in all subjects to detect asymptomatic aneurysms or dissections; therefore, a rigorous correlation of vascular lesions with study biomarkers could not be done. Finally, fresh plasma samples, required for more accurate platelet turnover measurements compared with MPV values, were no longer available when we considered the possibility of excess platelet turnover as a source of elevated TGF-β1.
In summary, we present evidence for changes in biomarker profiles in VEDS that include TGF-β1, TGF-β2, MCP-1, CRP, ICAM-1, VCAM-1, IL-8, and leptin. The absence of correlations with mutation type and disease severity for all but 1 (CRP) of the biomarkers studied suggests ongoing microvascular damage in patients with VEDS even in the absence of an event. TGF-β2 and IL-8 are altered and not affected by current drug treatment and could underlie disease specificity, unlike TGF-β1. The evidence for excess TGF-β2 secretion from VEDS fibroblasts independent of the organismal milieu suggests a probable role. Regional truncal adiposity and elevated leptin in VEDS point to the role of microvascular damage in adipocyte deposition and dysfunction. Finally, these data represent the first evidence for a preinflammatory state in VEDS and, after validation in affected tissues, open the door to treatment strategies by targeting specific cytokine pathways.
CLINICAL PERSPECTIVE
We explored the role of transforming growth factor-β pathway and other inflammatory biomarkers in plasma and dermal fibroblasts from patients with vascular Ehlers-Danlos syndrome (VEDS), which is caused by mutations in the COL3A1 gene. Analyses were done in terms of clinical disease severity, genotype-phenotype correlations, and body composition and fat deposition alterations. VEDS subjects were found to have elevated transforming growth factor-β1, transforming growth factor-β2, monocyte chemotactic protein-1, C-reactive protein, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in circulation compared with controls. Adipocyte dysfunction in VEDS was demonstrated through elevated leptin and decreased interleukin-8 in circulation. Dermal fibroblasts from VEDS subjects secreted greater amounts of transforming growth factor-β2 compared with controls. Patients with COL3A1 exon skipping mutations had higher plasma intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, and VEDS probands had abnormally high plasma C-reactive protein compared with affected patients identified through family members before any disease manifestations. Patients with VEDS had higher mean platelet volumes, suggesting increased platelet turnover because of ongoing vascular damage, as well as increased regional truncal adiposity. C-reactive protein is linked to disease state and may be a disease activity marker. These findings suggest that VEDS is a systemic disease with a major inflammatory component, and the above biomarkers should be considered when assessing patients with VEDS in the clinic.
